Home Investors News Press Releases 2005 Cyclacel Announces Appointment Of Judy Chiao MD As Vice President, Clinical Development And Regulatory Affairs

Cyclacel Announces Appointment Of Judy Chiao MD As Vice President, Clinical Development And Regulatory Affairs

Dundee , Scotland , UK - 12 May 2005 - Cyclacel Group plc (“Cyclacel”), the cell cycle-based biopharmaceutical company, announced today the appointment of Dr Judy H. Chiao, MD, as Vice President, Clinical Development and Regulatory Affairs. Dr Chiao will be responsible for the design and implementation of clinical trials and regulatory strategies pertaining to Cyclacel's drug portfolio. These include seliciclib, the leading orally available CDK inhibitor in Phase II clinical development ; CYC682, a novel, orally available nucleoside analog in Phase I trials; and the company's eight preclinical candidates.

Dr Chiao was previously Vice President, Oncology Clinical Research and Development, at Aton Pharma, Inc., a wholly owned subsidiary of Merck & Co. Prior to Aton's acquisition by Merck she was responsible for leading the clinical development of SAHA, a histone deacetylase inhibitor, in Phase II development for hematologic and solid tumor indications.

Before Merck and Aton she was a Senior Medical Reviewer, Division of Oncology Drug Products, at the Center for Drug Evaluation and Research , US Food and Drug Administration (FDA), where she was responsible for the development and regulation of investigational cancer drugs. Dr Chiao was a member of FDA working groups of health-related quality of life, chemoprevention and oncology disease endpoints. She presented the FDA's views in several New Drug Application reviews at Oncology Drug Advisory Committees (ODAC). In addition to her FDA position, she was an attending physician at the Clinical Center of the National Cancer Institute and the National Navy Medical Center where she participated in clinical research and patient care.

She earned her Bachelor of Science in Chemistry ( Summa Cum Laude ) at Columbia University , New York , and her medical degree from Harvard Medical School . Her Internship and Residency in Internal Medicine was carried out at Columbia-Presbyterian Medical Center , New York . She held a Research Fellowship in Molecular Pharmacology at Sloan Kettering Institute for Cancer Research and a Clinical Fellowship in Hematology/Oncology at Memorial Sloan Kettering Cancer Center , both in New York . She is a board-certified medical oncologist.

Spiro Rombotis , Cyclacel's Chief Executive Officer , said: “We are very pleased to welcome Dr Judy Chiao to Cyclacel. Judy has extensive experience in the oncology clinical and regulatory fields through her roles as a medical oncologist, in leading the successful clinical development of SAHA and as a Senior Medical Reviewer in the FDA's division that regulates oncology drugs. We expect that Judy will play a central role in planning and executing the clinical and registration strategies for Cyclacel's cancer drug candidates.”

About Cyclacel ( www.cyclacel.com )
Cyclacel is a biopharmaceutical company dedicated to the discovery, development and commercialization of novel, mechanism-targeted drugs to treat human cancers and other serious disorders. The company is currently evaluating seliciclib (CYC202), an orally-available Cyclin Dependent Kinase inhibitor, in Phase II clinical trials for the treatment of Non-Small Cell Lung Cancer and B-cell hematological malignancies. CYC682 is an orally-available, cell cycle modulating nucleoside analog in Phase I clinical trials for the treatment of cancer. Cyclacel has eight additional programs at preclinical stages.

Contacts for further information:

Cyclacel:	+44 (1382) 206 062
Spiro Rombotis, Chief Executive Officer
Paul McBarron, Chief Financial Officer
Buchanan Communications:	+44 (20) 7466 5000
Mark Court/Tim Anderson/Mary-Jane Johnson
Feinstein Kean Healthcare:	(617) 577 - 8110
Robert Gottlieb

  Go to top      Print page